GILD Gilead Sciences Inc

USD 70.67 2.18 3.182946
Icon

Gilead Sciences Inc (GILD) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - General | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 70.67

+2.18 (+3.18)%

USD 80.07B

0.03B

USD 83.12(+17.61%)

USD 72.72 (+2.90%)

Icon

GILD

Gilead Sciences Inc (USD)
COMMON STOCK | NSD
USD 70.67
0.00 0
Take a Tour
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 80.07B

USD 72.72 (+2.90%)

USD 70.67

Gilead Sciences Inc (GILD) Stock Forecast

USD 83.12
(+17.61%)

Based on the Gilead Sciences Inc stock forecast from 19 analysts, the average analyst target price for Gilead Sciences Inc is USD 83.12 over the next 12 months. Gilead Sciences Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Gilead Sciences Inc is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, Gilead Sciences Inc’s stock price was USD 70.67. Gilead Sciences Inc’s stock price has changed by +8.62% over the past week, +5.02% over the past month and -8.94% over the last year.

No recent analyst target price found for Gilead Sciences Inc
No recent average analyst rating found for Gilead Sciences Inc

Company Overview Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Strib...Read More

https://www.gilead.com

333 Lakeside Drive, Foster City, CA, United States, 94404

18,000

December

USD

USA

Adjusted Closing Price for Gilead Sciences Inc (GILD)

Loading...

Unadjusted Closing Price for Gilead Sciences Inc (GILD)

Loading...

Share Trading Volume for Gilead Sciences Inc Shares

Loading...

Compare Performance of Gilead Sciences Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for GILD

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Gilead Sciences Inc (Sector: Drug Manufacturers - General )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN
AstraZeneca PLC ADR +0.32 (+0.41%) USD245.11B 38.94 17.74

ETFs Containing GILD

Symbol Name GILD's Weight Expense Ratio Price(Change) Market Cap
BIS
ProShares UltraShort Nasd.. 7.41 % 0.95 % -0.47 (-2.71%) USD3.35M

Frequently Asked Questions About Gilead Sciences Inc (GILD) Stock

Based on ratings from 19 analysts Gilead Sciences Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 11 buy, sell and 15 hold ratings.

GILD stock's dividend yield is 4.79%. Our analysis grades GILD stock's dividend yield at A+. This means that GILD stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - General sector in the NSD exchange. Based on this GILD may be a good dividend stock for its sector.

Based on targets from 19 analysts, the average taret price for GILD is USD 83.12 over the next 12 months. The maximum analyst target price is USD 105 while the minimum anlayst target price is USD 65.

GILD stock's Price/Earning ratio is 178.53. Our analysis grades GILD stock's Price / Earning ratio at F. This means that GILD stock's Price/Earning ratio is above 86% of the stocks in the Drug Manufacturers - General sector in the NSD exchange. Based on this GILD may be a overvalued for its sector.

The last closing price of GILD's stock was USD 70.67.

The most recent market capitalization for GILD is USD 80.07B.

Based on targets from 19 analysts, the average taret price for GILD is projected at USD 83.12 over the next 12 months. This means that GILD's stock price may go up by +17.61% over the next 12 months.

Following are ETFs with the highest allocation to Gilead Sciences Inc's stock :

BIS

As per our most recent records Gilead Sciences Inc has 18,000 Employees.

Gilead Sciences Inc's registered address is 333 Lakeside Drive, Foster City, CA, United States, 94404. You can get more information about it from Gilead Sciences Inc's website at https://www.gilead.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...